skip to the content

First-line Avastin-based therapy: consistently proven to give patients more time without PD

Avastin first line: proven to deliver the longest survival time in NSCLC and give patients more time without PD

 
  • Precise VEGF inhibition with Avastin maintains control of tumour growth and metastasis.
  • Avastin in combination with platinum-doublet chemotherapy significantly increases TTP/PFS across patient subgroups compared with chemotherapy alone (AVF0757g).
  • Avastin-based therapy extends survival beyond that achieved with conventional chemotherapy, with OS beyond 1 year
    • unprecedented OS of 14.2 months in adenocarcinoma patients (ECOG 4599)
    • median OS of 14.6 months in the overall population (SAiL).
  • Avastin significantly and consistently improves PFS across patient subgroups (AVAiL and ECOG 4599).
  • The safety profile of Avastin is well established across broad patient populations and AEs are manageable (SAiL).
  • Based on the established need for angiogenesis inhibition throughout the course of the disease, an extensive trial programme is examining possible first-line combination therapies with Avastin (including Avastin plus Tarceva).
  • Preliminary efficacy data for first-line Avastin in combination with pemetrexed are promising.
 

Next

Back